The Drug Regulatory Authority of Pakistan (DRAP) has dismissed claims about a recent surge in the prices of essential medicines, calling such reports unfounded and inaccurate.
A DRAP spokesperson clarified that there has been no increase in the prices of critical drugs, including insulin and other life-saving medications. The authority emphasized that pharmaceutical companies are not allowed to independently raise the prices of essential medicines, as pricing remains strictly regulated.
The spokesperson further stated that DRAP is taking all necessary steps to ensure a steady and uninterrupted supply of medicines across the country. In this regard, the authority has issued two important advisories to pharmaceutical companies, directing them to secure raw materials from multiple sources to avoid any potential disruptions.
It was highlighted that around 85 percent of medicines used in Pakistan are manufactured locally, which significantly reduces dependency on imports. Despite concerns about possible logistical challenges, the supply chain remains stable, and there is currently no threat of shortages.
Industry representatives have also reassured that sufficient stocks of raw materials and finished products are available to meet demand for the next four to six months, ensuring continuity in supply.
In a separate development, DRAP has signed a memorandum of understanding with the Competition Commission of Pakistan (CCP) to strengthen coordination and regulatory oversight in the pharmaceutical sector.
Under this agreement, both institutions will collaborate through data sharing, joint research, and capacity-building initiatives. The partnership aims to establish a comprehensive system for monitoring medicine prices and availability, ensuring transparency and protecting consumers from unjustified price fluctuations.
Overall, DRAP reiterated its commitment to maintaining affordable medicine prices and ensuring consistent availability across Pakistan.
Also Read: DRAP Bans Sale of These Three Medicines
